Position in GUTS
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$18,920
New position
Shares Held
41,311
first reported quarter
Ownership
0.026%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Vanguard Global Advisers, LLC holds $766,427,404 across 390 Biotechnology names. GUTS ranks #309 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
555,733 | $248,157,013 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
228,491 | $176,541,286 | |
| 3 | MRNA |
Moderna, Inc.
|
735,962 | $37,386,869 | |
| 4 | INCY |
Incyte Corp
|
387,895 | $36,508,677 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
65,390 | $21,635,589 | |
| 6 | INSM |
INSMED Inc
|
109,003 | $17,824,170 | |
| 7 | TECH |
BIO-TECHNE Corp
|
330,500 | $17,271,930 | |
| 8 | RPRX |
Royalty Pharma plc
|
238,989 | $11,464,302 |
All Filings in GUTS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $18,920 | 41,311 | Shares | Defined | 2026-05-08 | |
| No filing history on record for this holder in this stock. | ||||||